CR10548A - 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen - Google Patents

18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen

Info

Publication number
CR10548A
CR10548A CR10548A CR10548A CR10548A CR 10548 A CR10548 A CR 10548A CR 10548 A CR10548 A CR 10548A CR 10548 A CR10548 A CR 10548A CR 10548 A CR10548 A CR 10548A
Authority
CR
Costa Rica
Prior art keywords
metil
androst
espirox
espiroeteres
19nor
Prior art date
Application number
CR10548A
Other languages
English (en)
Inventor
Rolf Bohlmann
Joachim Kuhnke
Jan Hubner
Norbert Gallus
Frederik Menges
Steffen Borden
Hans-Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR10548A publication Critical patent/CR10548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Abstract

La presente invencion describe los nuevos 18-metil-19-nor-androst-4-en-17,17-espiroeteres de la formula general I.
CR10548A 2006-06-29 2009-01-05 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen CR10548A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006030416A DE102006030416A1 (de) 2006-06-29 2006-06-29 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
CR10548A true CR10548A (es) 2009-01-27

Family

ID=38626491

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10548A CR10548A (es) 2006-06-29 2009-01-05 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen

Country Status (41)

Country Link
US (1) US7846917B2 (es)
EP (1) EP2038294B1 (es)
JP (1) JP5326085B2 (es)
KR (1) KR101440640B1 (es)
CN (1) CN101511857B (es)
AR (1) AR061736A1 (es)
AT (1) ATE490967T1 (es)
AU (1) AU2007263944B2 (es)
BR (1) BRPI0713934A2 (es)
CA (1) CA2656443C (es)
CL (1) CL2007001919A1 (es)
CO (1) CO6150134A2 (es)
CR (1) CR10548A (es)
CY (1) CY1111658T1 (es)
DE (2) DE102006030416A1 (es)
DK (1) DK2038294T3 (es)
DO (1) DOP2008000089A (es)
EC (1) ECSP089014A (es)
ES (1) ES2357698T3 (es)
GT (1) GT200800307A (es)
HK (1) HK1133659A1 (es)
HN (1) HN2008001934A (es)
HR (1) HRP20110161T1 (es)
IL (1) IL195935A0 (es)
MA (1) MA30596B1 (es)
MX (1) MX2009000082A (es)
MY (1) MY155015A (es)
NO (1) NO20090459L (es)
NZ (1) NZ573951A (es)
PE (1) PE20080995A1 (es)
PL (1) PL2038294T3 (es)
PT (1) PT2038294E (es)
RS (1) RS51722B (es)
RU (1) RU2440365C2 (es)
SI (1) SI2038294T1 (es)
TN (1) TNSN08518A1 (es)
TW (1) TWI413645B (es)
UA (1) UA94952C2 (es)
UY (1) UY30451A1 (es)
WO (1) WO2008000521A1 (es)
ZA (1) ZA200900673B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063496A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
CN104379149A (zh) * 2012-04-23 2015-02-25 拜耳医药股份有限公司 18-甲基-15β,16β-亚甲基-19-去甲-20-螺氧-4-烯-3-酮在治疗月经过多中的应用以及用于治疗子宫出血病症的包含18-甲基-15β,16β-亚甲基-19-去甲-20-螺氧-4-烯-3-酮的子宫内系统
WO2015055789A1 (en) 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
SG11201601688WA (en) * 2013-10-18 2016-05-30 Bayer Oy Intrauterine delivery system
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) * 2019-01-17 2021-01-26 浙江仙琚制药股份有限公司 替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798213A (en) 1971-01-25 1974-03-19 Merck & Co Inc 7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de) 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1223174A3 (en) 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

Also Published As

Publication number Publication date
EP2038294A1 (de) 2009-03-25
GT200800307A (es) 2009-11-03
RS51722B (en) 2011-10-31
PE20080995A1 (es) 2008-10-03
WO2008000521A1 (de) 2008-01-03
MY155015A (en) 2015-08-28
EP2038294B1 (de) 2010-12-08
DOP2008000089A (es) 2009-02-15
ECSP089014A (es) 2009-01-30
NO20090459L (no) 2009-03-10
UY30451A1 (es) 2008-01-31
JP5326085B2 (ja) 2013-10-30
MX2009000082A (es) 2009-01-23
DK2038294T3 (da) 2011-03-28
KR20090021294A (ko) 2009-03-02
HRP20110161T1 (hr) 2011-04-30
US7846917B2 (en) 2010-12-07
CN101511857A (zh) 2009-08-19
RU2440365C2 (ru) 2012-01-20
TNSN08518A1 (en) 2010-04-14
CL2007001919A1 (es) 2008-05-16
CY1111658T1 (el) 2015-10-07
BRPI0713934A2 (pt) 2012-12-04
CN101511857B (zh) 2012-10-31
SI2038294T1 (sl) 2011-04-29
NZ573951A (en) 2011-06-30
AR061736A1 (es) 2008-09-17
ES2357698T3 (es) 2011-04-28
AU2007263944A1 (en) 2008-01-03
DE502007005902D1 (de) 2011-01-20
AU2007263944B2 (en) 2013-07-18
IL195935A0 (en) 2009-09-01
TW200811193A (en) 2008-03-01
CA2656443A1 (en) 2008-01-03
ATE490967T1 (de) 2010-12-15
CA2656443C (en) 2014-10-07
RU2009102772A (ru) 2010-08-10
TWI413645B (zh) 2013-11-01
PT2038294E (pt) 2011-03-14
DE102006030416A1 (de) 2008-01-03
US20080153787A1 (en) 2008-06-26
HK1133659A1 (es) 2010-04-01
PL2038294T3 (pl) 2011-05-31
HN2008001934A (es) 2012-01-17
UA94952C2 (uk) 2011-06-25
MA30596B1 (fr) 2009-07-01
CO6150134A2 (es) 2010-04-20
JP2009541405A (ja) 2009-11-26
KR101440640B1 (ko) 2014-09-22
ZA200900673B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
PA8667201A1 (es) Nuevos compuestos farmaceuticos
ECSP10010722A (es) Compuestos orgánicos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
HN2006018410A (es) Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
UY30789A1 (es) Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CR9786A (es) Compuestos de bencimidazol-tiofeno
DOP2006000051A (es) Inhibidores de vegf-r2 y métodos
EA201170772A1 (ru) Органические соединения
CR10157A (es) Compuestos químicos
UY31688A1 (es) Plaguicidas
CO6362017A2 (es) Peptidos antivirales terapeuticos
ECSP088854A (es) Moduladores bencimidazolicos de vr1
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
PA8792401A1 (es) Fenilendiaminas
HN2009000856A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201000069A1 (ru) Новые гербициды